← Mechanisms of action
MS4A1
SINGLE PROTEINHomo sapiens
Preferred name: B-lymphocyte antigen CD20 ChEMBL ↗
Linked proteins
Drugs acting on this target (128)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| Ab89 | Adcc | experimental | mAb | CD20 |
| cpo107 | Adcc | experimental | mAb | MS4A1 adcc |
| f007 | Adcc | experimental | mAb | CD20 |
| mil62 | Adcc | experimental | mAb | CD20 |
| PSB102 | Adcc | experimental | mAb | CD20 |
| Ripertamab | Adcc | experimental | mAb | MS4A1 adcc |
| ublituximab (Briumvi) | Adcc | approved | mAb | MS4A1 adcc |
| azd5492 | Binding agent | experimental | mAb | MS4A1 binding agent |
| b007 | Binding agent | experimental | mAb | CD20 |
| cm355 | Binding agent | experimental | mAb | CD20 |
| Epcoritamab (Epkinly) | Binding agent | approved | mAb | MS4A1 binding agent |
| ex103 | Binding agent | experimental | mAb | MS4A1 binding agent |
| fbta05 | Binding agent | experimental | mAb | CD20 |
| gb261 | Binding agent | experimental | mAb | MS4A1 binding agent |
| glofitamab (Columvi) | Binding agent | approved | mAb | MS4A1 binding agent |
| ibritumomab tiuxetan (Zevalin) | Binding agent | approved | mAb | MS4A1 binding agent |
| Imm-0306 | Binding agent | experimental | mAb | CD20 |
| iph6501 | Binding agent | experimental | mAb | MS4A1 binding agent |
| jnj-80948543 | Binding agent | experimental | mAb | MS4A1 binding agent |
| jnj-87801493 | Binding agent | experimental | mAb | MS4A1 binding agent |
| js203 | Binding agent | experimental | mAb | MS4A1 binding agent |
| lfb-r603 | Binding agent | experimental | mAb | B-lymphocyte antigen CD20 binding agent |
| mbs303 | Binding agent | experimental | mAb | MS4A1 binding agent |
| mosunetuzumab (Lunsumio) | Binding agent | approved | mAb | B-lymphocyte antigen CD20 binding agent |
| mrg001 | Binding agent | experimental | mAb | CD20 |
| mt-3724 | Binding agent | experimental | Recombinant protein | B-lymphocyte antigen CD20 binding agent |
| obinutuzumab (gazyva) | Binding agent | approved | mAb | B-lymphocyte antigen CD20 binding agent |
| ocaratuzumab | Binding agent | experimental | mAb | B-lymphocyte antigen CD20 binding agent |
| ocrelizumab (ocrevus) | Binding agent | approved | mAb | B-lymphocyte antigen CD20 binding agent |
| ofatumumab (arzerra) | Binding agent | approved | mAb | B-lymphocyte antigen CD20 binding agent |
| regn1979 | Binding agent | experimental | mAb | B-lymphocyte antigen CD20 binding agent |
| rituximab (rituxan) | Binding agent | approved | mAb | B-lymphocyte antigen CD20 binding agent |
| tositumomab (Bexxar) | Binding agent | approved | mAb | MS4A1 binding agent |
| tqb2825 | Binding agent | experimental | mAb | CD20 |
| tru-015 | Binding agent | experimental | mAb | B-lymphocyte antigen CD20 binding agent |
| ublituximab (Briumvi) | Binding agent | approved | mAb | B-lymphocyte antigen CD20 binding agent |
| veltuzumab | Binding agent | experimental | mAb | B-lymphocyte antigen CD20 binding agent |
| xmab13676 | Binding agent | experimental | mAb | CD20 |
| fbta05 | Cross-linking agent | experimental | mAb | MS4A1 cross-linking agent |
| lfb-r603 | Cross-linking agent | experimental | mAb | MS4A1 cross-linking agent |
| xenogeneic cd20 dna | Immunity, active | experimental | Vaccine | MS4A1 immunity, active |
| 4scar20 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| ace1831 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| allo-quadcar01-t | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| allogeneic cd20 car-t cell | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| anti-cd19 and anti-cd20 bicistronic car t- cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| anti-cd19/20-car vector-transduced t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| anti-cd19/cd20/cd22 car t-cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| bbt369 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| c-car066 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| car-20/19-t | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| car-t targeted cd19/cd20/cd22/cd30 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| car20.19.22 cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| car20(nap)-t | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| cart20 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| cd19/cd20 bispecific car-t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| cd19/cd20/bcma car t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| cd20 car-t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| cd20/bcma-directed car-t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| cd20/cd22 targeted car t-cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| cd20bi-aatc | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| ct1190b | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| decitabine-primed tandem car19/20 engineered t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| di-leu16-il2 | Immunity, passive | experimental | Recombinant protein | MS4A1 immunity, passive |
| ft522 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| genetically modified t cells # 1138 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| imj995 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| impt-314 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| jwcar201 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| jwcar239 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| kite-363 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| lcar-aio cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| lucar-e9d | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| lucar-g39d | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| lv20.19 car t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| ly007 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| lyl314 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| ma-20 | Immunity, passive | experimental | mAb | MS4A1 immunity, passive |
| mosunetuzumab (Lunsumio) | Immunity, passive | approved | mAb | MS4A1 immunity, passive |
| p-cd19cd20-allo1 cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| rqr8/atrbc1 car t | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| ucart20x22 | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| universal dual specificity cd19 and cd20 or cd22 car-t cells | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| zamtocabtagene autoleucel | Immunity, passive | experimental | Cell therapy | MS4A1 immunity, passive |
| anti-cd20 b9e9 scfv-streptavidin fusion protein | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| bat4306f | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| bat4406f | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| bcd-132 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| bcd-281 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| cd20-tcb | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| cho-h01 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| cnd261 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| cu-64 rituximab | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| fbta05 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| igm-2323 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| ign002 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| imm0306 | Inhibitor | experimental | Recombinant protein | MS4A1 inhibitor |
| ipm514 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| jmt601 | Inhibitor | experimental | Recombinant protein | MS4A1 inhibitor |
| lfb-r603 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| monoclonal antibody cd20 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| msc303 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| mt-3724 | Inhibitor | experimental | Recombinant protein | MS4A1 inhibitor |
| obinutuzumab (gazyva) | Inhibitor | approved | mAb | MS4A1 inhibitor |
| ocaratuzumab | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| ocrelizumab (ocrevus) | Inhibitor | approved | mAb | MS4A1 inhibitor |
| ofatumumab (arzerra) | Inhibitor | approved | mAb | MS4A1 inhibitor |
| prizloncabtagene autoleucel | Inhibitor | experimental | Cell therapy | MS4A1 inhibitor |
| pro13192 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| regn1979 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| rituximab (rituxan) | Inhibitor | approved | mAb | MS4A1 inhibitor |
| ro7121932 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| sbi-087 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| sctb35 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| TC99M nofetumomab merpentan (Verluma) | Inhibitor | approved | mAb | MS4A1 inhibitor |
| tositumomab (Bexxar) | Inhibitor | approved | mAb | MS4A1 inhibitor |
| tru-015 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| ublituximab (Briumvi) | Inhibitor | approved | mAb | MS4A1 inhibitor |
| veltuzumab | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| xmab13676 | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| zebetuzumab | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| zr89-rituximab | Inhibitor | experimental | mAb | MS4A1 inhibitor |
| ocrelizumab (ocrevus) | Other | approved | mAb | MS4A1 other |
| ublituximab (Briumvi) | Other | approved | mAb | MS4A1 other |
| 111in zevalin | Radiodepletion | experimental | mAb | MS4A1 radiodepletion |
| 131i-rituximab | Radiodepletion | experimental | mAb | MS4A1 radiodepletion |
| ibritumomab tiuxetan (Zevalin) | Radiopharmaceutical | approved | mAb | MS4A1 radiopharmaceutical |